S17 Ep56: Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS
About this episode
Dr. Neil D. Gross discusses systemic therapy selection and sequencing in advanced cutaneous squamous cell carcinoma.
In today’s episode, we spoke with Neil D. Gross, MD, FACS. Dr Gross is the medical director of Perioperative Surgical Services, section chief of Oropharynx Cancer, Surgery, and professor of head and neck surgery at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Gross discussed the key biological and clinical distinctions between cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), noting that although BCC is more indolent and less responsive to systemic therapies, including immunotherapy, CSCC carries a meaningful risk of nodal and distant metastases and has demonstrated robust responses to anti–PD-1 therapy, with approximately half of patients achieving a significant response. He emphasized the importance of early multidisciplinary evaluation, with resectability serving as a critical first branch point in treatment planning. For patients with unresectable or metastatic CSCC, anti–PD-1 therapy is now the established standard of care. For borderline resectable patients, such as those at risk for significant functional loss from surgery, upfront systemic therapy offers the potential to preserve function and achieve…
More episodes of OncLive® On Air
- S17 Ep59: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
- S17 Ep58: DLBCL 2026 UPDATE
- S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
- S17 Ep55: Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis
- S17 Ep54: Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
- S17 Ep53: Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us
Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.